Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings...
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0251 | 4.92156862745 | 0.51 | 0.59 | 0.49 | 247796 | 0.53915637 | CS |
4 | -0.0909 | -14.5207667732 | 0.626 | 0.65 | 0.475 | 208120 | 0.53925934 | CS |
12 | -0.1349 | -20.1343283582 | 0.67 | 0.718 | 0.475 | 149362 | 0.58819059 | CS |
26 | -0.2016 | -27.3652775892 | 0.7367 | 0.78 | 0.475 | 159509 | 0.64404207 | CS |
52 | -0.5949 | -52.6460176991 | 1.13 | 1.56 | 0.475 | 167054 | 0.82900528 | CS |
156 | -4.3949 | -89.1460446247 | 4.93 | 5.16 | 0.475 | 187745 | 1.53706832 | CS |
260 | -21.4549 | -97.5666211915 | 21.99 | 43.07 | 0.475 | 190259 | 6.52076304 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約